Ontology highlight
ABSTRACT: Background
Transfusion of red blood cells (RBC) is recommended in septic shock and the majority of these patients receive RBC transfusion in the intensive care unit (ICU). However, benefit and harm of RBCs have not been established in this group of high-risk patients.Methods/design
The Transfusion Requirements in Septic Shock (TRISS) trial is a multicenter trial with assessor-blinded outcome assessment, randomising 1,000 patients with septic shock in 30 Scandinavian ICUs to receive transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 7 g/dl or 9 g/dl, stratified by the presence of haematological malignancy and centre. The primary outcome measure is 90-day mortality. Secondary outcome measures are organ failure, ischaemic events, severe adverse reactions (SARs: anaphylactic reaction, acute haemolytic reaction and transfusion-related circulatory overload, and acute lung injury) and mortality at 28 days, 6 months and 1 year.The sample size will enable us to detect a 9% absolute difference in 90-day mortality assuming a 45% event rate with a type 1 error rate of 5% and power of 80%. An interim analysis will be performed after 500 patients, and the Data Monitoring and Safety Committee will recommend the trial be stopped if a group difference in 90-day mortality with P ≤0.001 is present at this point.Discussion
The TRISS trial may bridge the gap between clinical practice and the lack of efficacy and safety data on RBC transfusion in septic shock patients. The effect of restrictive versus liberal RBC transfusion strategy on mortality, organ failure, ischaemic events and SARs will be evaluated.
SUBMITTER: Holst LB
PROVIDER: S-EPMC3679866 | biostudies-literature | 2013 May
REPOSITORIES: biostudies-literature
Holst Lars B LB Haase Nicolai N Wetterslev Jørn J Wernerman Jan J Aneman Anders A Guttormsen Anne B AB Johansson Pär I PI Karlsson Sari S Klemenzson Gudmundur G Winding Robert R Nebrich Lars L Albeck Carsten C Vang Marianne L ML Bülow Hans-Henrik HH Elkjær Jeanie M JM Nielsen Jane S JS Kirkegaard Peter P Nibro Helle H Lindhardt Anne A Strange Ditte D Thormar Katrin K Poulsen Lone M LM Berezowicz Pawel P Bådstøløkken Per M PM Strand Kristian K Cronhjort Maria M Haunstrup Elsebeth E Rian Omar O Oldner Anders A Bendtsen Asger A Iversen Susanne S Langva Jørn-Åge JÅ Johansen Rasmus B RB Nielsen Niklas N Pettilä Ville V Reinikainen Matti M Keld Dorte D Leivdal Siv S Breider Jan-Michael JM Tjäder Inga I Reiter Nanna N Gøttrup Ulf U White Jonathan J Wiis Jørgen J Andersen Lasse Høgh LH Steensen Morten M Perner Anders A
Trials 20130523
<h4>Background</h4>Transfusion of red blood cells (RBC) is recommended in septic shock and the majority of these patients receive RBC transfusion in the intensive care unit (ICU). However, benefit and harm of RBCs have not been established in this group of high-risk patients.<h4>Methods/design</h4>The Transfusion Requirements in Septic Shock (TRISS) trial is a multicenter trial with assessor-blinded outcome assessment, randomising 1,000 patients with septic shock in 30 Scandinavian ICUs to recei ...[more]